MAGL inhibitors

A compound having the structure of Formula (I):

• wherein:
• R1 is —R14, —OR3, —SR4, —S(O)2R4, or —C≡C—(CR6R7)—R8;
• each R2 is independently selected from C1-6alkyl, halogen, —CN, C1-6haloalkyl, —C1-6alkyl(heterocycloalkyl), —OR17, and —C(O)NR18R19;
• R3 is —(CR6R7)m—R8, —(CR6R7)p—Y—(CR6R7)q—R8, or —(CR6R7)t—C3-6cycloalkyl-R8;
• R4 is —(CR6R7)m—R8′, —(CR6R7)v—C(O)OH, or —(CR6R7)p—Y—(CR6R7)q—R8;
• Y is —O— or —N(R22)—;
• each R6 and R7 is each independently selected from H, F, and C1-6alkyl;
• or R6 and R7, together with the carbon to which they are attached, form a C3-6cycloalkyl ring;
• R8 is —C(O)OR9, —C(O)R10, or —C(O)O—(CR12R13)—OC(O)R11;
• R8′ is —C(O)OR9′, —C(O)R10′, or —C(O)O—(CR12R13)—OC(O)R11;
• R9 is H or C1-6alkyl;
• R9′ is C1-6alkyl;
• R10 is C1-6alkyl or —NHSO2R21;
• R10′ is C2-6alkyl or —NHSO2R21;
• R11 is C1-6alkyl or C1-6alkoxy;
• R12 and R13 is each independently H or C1-6alkyl;
• R14 is —(CR15R16)m—R8 or —(CR6R7)p—Y—(CR6R7)q—R8;
• each R15 and R16 is each independently selected from H, F, and C1-6alkyl;
• each R17 is independently selected from H, C1-6alkyl, C1-6haloalkyl, and C3-6cycloalkyl;
• each R18 and R19 is each independently selected from H, C1-6alkyl, C3-6cycloalkyl, aryl, and heteroaryl;
• or R18 and R19, together with the nitrogen to which they are attached, form a heterocycloalkyl ring optionally substituted with one, two, or three R20;
• each R20 is independently selected from halogen, C1-6alkyl, C1-6haloalkyl, oxo, —CN, and C3-6cycloalkyl;
• R21 is C1-6alkyl or C3-6cycloalkyl;
• R22 is H, C1-6alkyl, or —SO2R23;
• R23 is C1-6alkyl;
• m is 1, 2, 3 or 4;
• n is 0, 1, 2, 3, or 4;
• p is 2, 3, or 4;
• q is 1, 2, or 3;
• t is 0, 1, or 2;
• and
• v is 3 or 4;
• or a pharmaceutically acceptable salt or solvate thereof.